SK Biopharm Presents 'Cenobamate' Research Findings at American Neurological Association Meeting

SK Life Science, the U.S. subsidiary of SK Biopharm, announced on the 7th that it will present key research results on cenobamate (U.S. brand name Xcopri®) at the American Academy of Neurology (AAN) Annual Meeting.

From the 5th to the 9th (local time), SK Life Science will present clinical results and real-world data (RWD) supporting cenobamate’s contribution to seizure reduction and optimization of epilepsy management at the 77th AAN meeting held in San Diego, California.

Louis Ferrari, Vice President of Medical Affairs at SK Life Science, stated, "SK Life Science aims to establish a new standard in epilepsy management by creating meaningful changes in the lives of epilepsy patients through research and education. Seizure freedom remains an important treatment goal for many patients, but achieving it is a challenging task. This study is significant in that it uses responsive neurostimulation (RNS) data as an objective measure to evaluate the effectiveness of cenobamate and other adjunctive antiseizure medications (ASM)."

The study presented at AAN is a U.S.-based multicenter retrospective observational study involving 37 adult patients aged 18 or older with focal seizures who took at least 50 mg/day of cenobamate as adjunctive therapy for a minimum of two weeks. The RNS data of these patients were analyzed. The results showed a significant reduction in the frequency of epileptiform events during the treatment period (12 weeks) compared to baseline (8 weeks), meeting the primary endpoint. The frequency of epileptiform events decreased by approximately 84%, from an average of 15.7 events per 28 days at baseline to 2.5 events per 29 days at the final observation point.

The most common adverse reactions reported were dizziness and somnolence. However, these were improved by gradually increasing the dose of cenobamate or reducing the dose of other concomitant antiseizure medications.

Meanwhile, SK Life Science will present a total of six studies analyzing the therapeutic effects, safety, and therapeutic potential of cenobamate from multiple perspectives at this conference. Through research involving diverse patient groups, these results suggest the broad therapeutic possibilities of cenobamate and are expected to contribute to future treatment strategy development.

The abstracts presented at the American Academy of Neurology, including the six studies presented by SK Life Science, are available on the official AAN website.

This content was produced with the assistance of AI translation services.